A binary Xpovio catalyst is set for March.
ApexOnco Front Page
Recent articles
BeOne terminates a MUC1-targeting project.
Innovent’s perseverance with a cytokine approach is rewarded with $1.2bn from Takeda.
The company will acquire ImCheck for €350m.
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
A quartet of failed tiragolumab trials featured at ESMO over the weekend.
